Libo Pharma Corp. (TPEX:7888)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
40.90
+0.10 (0.25%)
At close: Apr 28, 2026
-23.98%
Market Cap 3.08B
Revenue (ttm) n/a
Net Income (ttm) -296.30M
Shares Out 75.24M
EPS (ttm) -4.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 120,330
Average Volume 53,355
Open 40.80
Previous Close 40.80
Day's Range 40.70 - 41.50
52-Week Range 40.00 - 69.00
Beta n/a
RSI 32.79
Earnings Date Jun 18, 2026

About Libo Pharma

Libo Pharma Corp., a clinical-stage biopharmaceutical company, engage in novel therapeutics development in the field of oncology and hematology. The company offers LIB-101, an interleukin-12 (IL-12) cytokine immunotherapy for innate immunity, adaptive immunity, and hematopoiesis. Libo Pharma Corp. was founded in 2017 and is based in Taipei, Taiwan. [Read more]

Industry Pharmaceutical Preparations
Founded 2017
Employees 31
Stock Exchange Taipei Exchange
Ticker Symbol 7888
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.